The Glasgow prognostic score can be a predictor of mortality in acute exacerbation of chronic obstructive pulmonary disease

ABSTRACT

Aim: To determine the prognostic value of Glasgow Prognostic Score (GPS) in acute exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) requiring hospitalization.

Methods: Hospital electronic database of 129 patients with AECOPD was retrospectively searched and CRP levels, complete blood count, arterial blood gas (ABG) values and pulmonary function test (PFT) parameters of patients were recorded. Hospital mortality and need for ICU transfer were determined as adverse outcomes from files of cases.

Results: 106 of 129 patients were male (82.2%) and rest of them were female (17.8%). GPS 0 was not observed in any patient, GPS 1 was observed in 101 patients, and GPS 2 was observed in 28 patients. The rate of adverse outcomes (ICU/Ex) was significantly increased in the GPS 2 group when compared to the GPS 1 group (X²:7.631, p < 0.01). Logistic regression analysis indicated that pH≤7.35 (p < 0.05, OR: 5.65, CI: 1.35–23.58%) and GPS 2 score (p < 0.05, OR: 5.52, CI: 1.45–20.97%) were independent predictors for adverse outcomes for AECOPD.

Conclusion: Our results demonstrate that the GPS may have predictive value for adverse outcomes in patients with AECOPD.

KEYWORDS:

• COPD
• acute exacerbation
• mortality
• need for intensive care unit

Article Highlights

• Glasgow Prognostic Score (GPS) is associated with adverse outcomes in patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD).

• GPS can be considered as an independent marker of poor prognosis in these patients.

• GPS is a scoring system based on inflammation derived from the evaluation of acute-phase proteins such as C-reactive protein (CRP) and albümin.

• The calculation of GPS is an applicable simply and inexpensive method.

GPS can be easily interpreted and it can predict short-term mortality risk of patients with AECOPD.

Author Contributions

Mutlu Kuluöztürk: designed research/study, performed research/study and wrote the paper Figen Deveci: analyzed data and wrote the paper. All authors read and approved the final manuscript.

Declaration of Interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer Disclosures

A peer reviewer on this manuscript is an employee of GlaxoSmithKline.

Additional information

Funding

This paper was not funded.